Search clinical trials for: Risperidone Consta - Long Acting Injection

Total 80881 results

Hospital Clinic of Barcelona

Unknown

Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization (PK-VIT-D)

Obesity | Gastrectomy | Gastric Bypass

Spain
Réseau de Santé Vitalité Health Network
Janssen Inc.

Unknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Schizophrenia Spectrum and Other Psychotic Disorders

Canada
University of Pittsburgh
Janssen Pharmaceuticals

Completed

Risperdal Consta for Bipolar Disorder

Bipolar I Disorder

United States
Xian-Janssen Pharmaceutical Ltd.

Terminated

An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

Schizophrenia
Janssen Cilag N.V./S.A.

Completed

A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

Schizophrenia

South Africa
Janssen, LP

Completed

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) (SOURCE)

Schizophrenia

United States
Janssen-Ortho Inc., Canada

Completed

A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

Canada
Janssen-Ortho Inc., Canada

Terminated

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Schizophrenia

Canada, United Kingdom, Australia, Ireland
Janssen Pharmaceutica N.V., Belgium

Completed

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

Schizophrenia

United Kingdom, Slovenia, Denmark, Finland, France, Greece, Israel, Norway, Sweden, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection

Psychotic Disorders | Schizophrenia
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Schizophrenia

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia

United States, Brazil, Mexico
Northwestern University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

Schizophrenia | Schizoaffective Disorder

United States
Dartmouth-Hitchcock Medical Center
Janssen, LP

Completed

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

Psychotic Disorders | Schizophrenia | Substance Abuse | Alcohol Abuse

United States
Shanghai Mental Health Center

Unknown

Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime

Schizophrenia

China
Northwell Health
National Alliance for Research on Schizophrenia and Depression; The Zucker...

Terminated

Optimizing Response in Psychosis Study (ORP)

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychotic Disorder Not Otherwise Specified

United States
Vanderbilt University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder? (Consta)

Bipolar Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Germany, Spain, India, Russian Federation, Czech Republic, Austria, Hungary, Lithuania, Bulgaria, Estonia, Poland, France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Psychotic Disorders | Schizophrenia

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

Bipolar Disorder

China, Taiwan, Colombia, India, Malaysia, Russian Federation, South Africa, Greece, Peru, Germany, Mexico, Lebanon, Indonesia, Philippines, Jordan
Janssen-Cilag Ltd.

Completed

Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia

Schizophrenia

Brazil
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia

Schizophrenia | Schizoaffective Disorder

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)

Mental Disorders | Schizophrenia | Tranquilizing Agents | Therapeutic Uses | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder

Schizophrenia

Korea, Republic of
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment

Schizophrenia | Schizoaffective Disorders
Janssen Scientific Affairs, LLC

Completed

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Schizophrenia | Bipolar Disorder

United States
Janssen-Cilag Ltd.

Completed

An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
Xian-Janssen Pharmaceutical Ltd.

Completed

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia

Schizophrenia

China
Janssen-Cilag International NV

Completed

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Schizophrenia

France, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
Janssen Pharmaceutica N.V., Belgium

Completed

A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

Schizophrenia
Janssen Cilag N.V./S.A.

Completed

An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone (e-STAR)

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.

Schizophrenia | Schizoaffective Disorder
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.

Schizophrenia
Janssen, LP

Completed

Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia
Janssen-Ortho Inc., Canada

Completed

A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder

Bipolar Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

Psychotic Disorders | Schizophrenia
Janssen, LP

Completed

A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia

3

Subscribe